89bio

89bio is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies for the treatment of liver and cardiometabolic diseases. Their lead product candidate, pegozafermin, is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). 89bio believes that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with these conditions.

The company is headquartered in San Francisco, California with operations in Herzliya, Israel. 89bio has a strong leadership team with experience in building and leading fully commercialized companies, and they are committed to bringing this potential new therapy to patients efficiently. They are currently focused on enrolling and conducting the clinical trials necessary to apply for, and potentially gain, regulatory approvals to make their medicines available to patients.

89bio offers a hybrid work environment, allowing employees the flexibility to work both in the office and remotely. They also provide a monthly home office stipend to support remote workers. Additionally, the company has a strong focus on work-life balance, offering flexible scheduling and generous paid time off.

89bio offers a comprehensive benefits package that includes medical, dental, and vision insurance, disability and life insurance, and tax-savings benefits, all provided through TriNet. Employees also enjoy a variety of additional perks, such as the opportunity to earn up to 150% of bonus targets, a holiday shutdown, a 401(k) match, a hybrid work environment, and a monthly home office stipend.

89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. They are focused on addressing the growing needs of patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) through their lead candidate, pegozafermin, an investigational glycopegylated FGF21 analog.

89bio promotes a culture that is patient-centric, ethical, authentic, collaborative, entrepreneurial, and science-driven. They value diversity, equity, and inclusion, and foster a welcoming environment where everyone has a voice. Their team embraces a start-up mindset, cultivates an entrepreneurial spirit, and prioritizes creating opportunities for their employees.

89bio is committed to fostering an inclusive and equitable workplace that values diversity. They strive to represent a variety of groups within their company and actively work to ensure that their norms, practices, and policies are equitable. To further promote inclusivity, 89bio regularly conducts anonymous employee surveys to understand their experiences and use the data to make improvements.